ArticleMolecular cancer therapeutics2018

APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.

Cheng-Yu Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.